WO1996028176A1 - Composition destinee a induire la tolerance orale et utilisation de ladite composition - Google Patents
Composition destinee a induire la tolerance orale et utilisation de ladite composition Download PDFInfo
- Publication number
- WO1996028176A1 WO1996028176A1 PCT/EP1996/001004 EP9601004W WO9628176A1 WO 1996028176 A1 WO1996028176 A1 WO 1996028176A1 EP 9601004 W EP9601004 W EP 9601004W WO 9628176 A1 WO9628176 A1 WO 9628176A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- quail
- egg
- composition
- eggs
- induction
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 title claims abstract description 46
- 230000006698 induction Effects 0.000 title claims abstract description 27
- 241000286209 Phasianidae Species 0.000 claims abstract description 69
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 15
- 238000009472 formulation Methods 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 241000124008 Mammalia Species 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 5
- 235000016709 nutrition Nutrition 0.000 claims abstract description 5
- 235000013601 eggs Nutrition 0.000 claims description 89
- 239000000427 antigen Substances 0.000 claims description 36
- 102000036639 antigens Human genes 0.000 claims description 34
- 108091007433 antigens Proteins 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 15
- 235000014633 carbohydrates Nutrition 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 238000007710 freezing Methods 0.000 claims description 6
- 230000008014 freezing Effects 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical group O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 235000013681 dietary sucrose Nutrition 0.000 claims description 3
- 235000012907 honey Nutrition 0.000 claims description 3
- 230000001506 immunosuppresive effect Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229960004793 sucrose Drugs 0.000 claims description 3
- 102000008072 Lymphokines Human genes 0.000 claims description 2
- 108010074338 Lymphokines Proteins 0.000 claims description 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims description 2
- 210000003278 egg shell Anatomy 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 239000002671 adjuvant Substances 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000012581 transferrin Substances 0.000 description 8
- 210000002969 egg yolk Anatomy 0.000 description 7
- 230000037406 food intake Effects 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 238000011795 OF1 mouse Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000014103 egg white Nutrition 0.000 description 6
- 210000000969 egg white Anatomy 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 102000004338 Transferrin Human genes 0.000 description 5
- 108090000901 Transferrin Proteins 0.000 description 5
- 208000026935 allergic disease Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 235000013330 chicken meat Nutrition 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000334119 Coturnix japonica Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 206010002199 Anaphylactic shock Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 238000011735 C3H mouse Methods 0.000 description 2
- 241000334123 Coturnix coturnix coturnix Species 0.000 description 2
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000202327 Coturnix chinensis Species 0.000 description 1
- 241000288030 Coturnix coturnix Species 0.000 description 1
- 241000555973 Coturnix novaezelandiae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000272458 Numididae Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- composition for oral tolerance induction and use thereof are provided.
- the present invention relates to the use of quail's egg or quail's egg lyophilisate as an adjuvant for induction of oral tolerance (OT).
- OT oral tolerance
- OT Oral tolerance, or systemic unresponsiveness to ingested antigen, was first described at the turn of the century. It is usually effected by oral administration of minimal and very progressively increasing doses of antigen under medical surveillance favouring the systemic unresponsiveness to the ingested antigen.
- OT may thus be employed to treat or cure allergies, auto-immune diseases, pathological situations where auto-immunity is an aggravating factor, induction of tolerance prior to organ transplants, etc.
- OT could be induced in several experimental animal models but its induction varied e.g. with: the structure of the antigen and its sensitivity to proteolysis the dose of antigen ingested the chronology of administration the method and duration of administration the species and strains of the animals employed the age and sex of the animals the mode of feeding.
- the present invention provides a solution to this problem by providing an adjuvant for the induction of OT which improves the outcome of the treatment, i.e. which enhances the effect on OT, and gives it the required reliability.
- EP 0 032 344 describes a therapeutic effect with quail's egg lyophilisate in the treatment of immuno-allergic diseases it is silent with respect to the induction of oral tolerance.
- composition of the invention therefore provides for a composition for enteral administration comprising a quail's egg lyophilisate, characterized in that the quail's egg lyophilisate is produced in the presence of 5 to 40% by weight of carbohydrate, based on the weight of the quail's egg content, (hereinafter referred to as composition of the invention)
- Quail's eggs or the composition of the invention are used in combination with an antigen for which an immune response of the tolerance type, i.e. systemic unresponsiveness, is to be achieved, in order to enhance the OT-inducing effect.
- the antigen can be administered prior to the administration of the adjuvant, subsequently or simultaneous with the adjuvant.
- the antigen is mixed together with the composition of the invention and administered simultaneously.
- the invention further provides for the use of quail's eggs or of a composition of the invention in the preparation of a medicament or nutritional formulation for the enhancement of induction of oral tolerance in mammals.
- the mammals are humans.
- the invention also provides a method for enhancing the OT-inducing effect of an antigen in a mammal, which comprises administering enterally, prior to, subsequent to or simultaneous with the antigen to which an immune response of the tolerance type is to be achieved, an amount of quail's egg or of a composition of the invention which is effective for enhancing the OT-inducing effect of the antigen.
- Quail's egg as used herein refers to egg white and/or yolk, OT-inducing components of egg white and/or yolk or mixtures thereof.
- quail's egg refers to egg white and yolk, i.e. whole egg content.
- Any quail's eggs may be used according to the invention.
- Typical examples of eggs suitable as an adjuvant for the induction of OT include those from the following quail types: Coturnix-coturnix, Coturnix-delagorguei, Coturnix- novaeZealandiae, Coturnix-chinensis, Coturnix-coturnix japonica, Excalfactoria and strain MINA B.
- the eggs may be fertilized or unfertilized, fertilized eggs being preferred.
- MINA B is a cross of the wild quail Coturnix-coturnix-coturnix and the quail Coturnix-coturnix-japonica.
- MINA B is a cross of the wild quail Coturnix-coturnix-coturnix and the quail Coturnix-coturnix-japonica.
- eggs of other quail species have revealed the same properties as the fertilized eggs of MINA B, this effect was never obtained with eggs of chickens, ducks, guinea fowl or pheasants.
- the dosage of the composition of the invention for humans per day is preferably from 2 to 12 g. It is normally administered as cure of nine consecutive days followed by nine consecutive days without treatment and an optional further cure of nine consecutive days.
- the corresponding dosage of fresh quail's egg is from 1 to 6 eggs per day.
- Antigen as used herein refers to soluble or particulate antigen such as allergens, auto-antigens, allo-antigens, xeno-antigens, proteins, glycoproteins, cells such as red blood cells, bacteria, viruses, etc.
- the dosage of antigen to be employed to obtain the desired effect will depend on the particular treatment and the desired oral tolerance. Such dosages are known or can be established by the skilled person in a manner known per se for conventional treatment with antigen to induce OT.
- the amount of antigen to be administered lies in the range of from 1 ng to 1 g, preferably from 1 mg to 500 mg, particularly preferred about 100 mg.
- the antigen may be administered enterally such as by oral feeding or intragastric feeding or by inhalation.
- OT is also used herein when reference is made to administration of antigen by inhalation or intragastric feeding because OT is a term known in the art and describes the same effect that is observed with the present invention.
- OT administration of antigen and quail's egg or the composition of the invention should be started at least five days before the challenge with the immune response inducing agent, whereby the duration of administration may vary.
- induction of OT can be effected after treatment according to the invention for three weeks, however, improvements of the clinical condition may already be observed after one week.
- Induction of OT can further be enhanced through the "idiotypic network" if auto ⁇ antibodies are administered in combination with the quail's egg or the composition of the invention in combination with the antigen as set out above.
- auto-antibodies a higher rate of induction of OT is achieveable.
- the dosage of auto ⁇ antibodies having an enhancing effect on induction of OT is within the range of 1 ⁇ g to 10 mg per day during 1 to 10 days.
- the autoantibodies can be administered prior to, subsequent to or simultaneous with the quail's egg or the composition of the invention in combination with the antigen, whereby mixing the quail's egg or composition of the invention with antigen and auto-antibody and administering all these ingredients simultaneously is preferred.
- TGF beta 1 Transforming Growth Factor
- the invention further provides the use of quail's eggs or of a composition of the invention in the preparation of a medicament or nutritional formulation for the induction of production of lymphokines with immunosuppressive properties.
- composition of the invention can be prepared by lyophilisation of egg contents according to known methods.
- Some preferred methods of lyophilisation are as follows:
- the batches of eggs are steeped in an antiseptic solution, broken en masse, filtered, centrifuged, and mixed with carbohydrates in a proportion of 5 to 40% (w/w), preferably 5 to 20% (w/w).
- Suitable examples of carbohydrates that may be used in this application are disaccharides such as maltose, trehalose or lactose, monosaccharides such as glucose, fructose, galactose or carbohydrate mixtures such as honey.
- the carbohydrate is preferably saccharose or honey.
- the mixture may then optionally be pasteurized at a temperature not exceeding 37°C.
- Lyophilization is carried out with a freezing stage which should not drop below -42°C, at a rate of cooling of 5°C/min, at a pressure of 0.01 torr.
- An alternative consists in freezing the egg contents abruptly with liquid nitrogen. Drying should be effected at less than 25°C at a pressure of 0.003 to 0.006 torr. Afterwards, the powder is divided into sachets of 6 g which corresponds to 3 eggs.
- the quail's eggs are separated into white and yolk according to a manual or industrial procedure especially adapted to quail's eggs and egg white and yolk are mixed separately with the carbohydrates. Then the whites are lyophilised according to a standard procedure and the yolks are lyophilized by freezing in liquid nitrogen. Drying should be effected at less than 25°C at a pressure of 0 003 to 0.006 torr. Afterwards, the powder is divided into sachets of 6 g which corresponds to 3 eggs.
- a standard procedure for lyophilising the egg whites is e.g. as follows: the egg whites are put into a petri dish whereby the thickness of the egg layer should not exceed 2 cm, then the petri dish is put in a -80°C-freezer overnight, whereafter it is transferred to a dryer chamber where for the primary drying of 24 hours the condenser temperature is -45°C and the chamber pressure 0.01 torr and for the secondary drying of 6 to 12 hours the shelf temperature is +5°C and the pressure 0.01 torr.
- the invention further provides for a process for manufacturing quail's egg Iyophilisates comprising the steps of: a) separating egg contents from eggshells, b) adding 5 to 40% (w/w) of carbohydrate and mixing it with the egg contents, c) freezing and drying the mixture.
- composition of the invention may be formulated into conventional enteral administration forms, such as granules, tablets, capsules, liquids, powders, etc.
- enteral administration forms such as granules, tablets, capsules, liquids, powders, etc.
- a physiologically acceptable formulation form such as a capsule or tablet form
- Typical pharmacologically acceptable formulation forms for oral administration will further comprise pharmacologically acceptable diluents, carriers, vitamins, spices, pigments and/or other adjuvants well known to the skilled person to be suitable for incorporation into such formulation and preferably also antigen.
- the composition of the invention is administered in powder form as this form is most convenient to mix the lyophilisate with the appropriate antigen.
- the egg contents are frozen abruptly with liquid nitrogen and dried at less than 25°C at a pressure of 0.003 to 0.006 torr. Afterwards, the powder is divided into sachets of 6 g which corresponds to 3 eggs.
- Balb/c mice do not produce OT to soluble antigens, whereas it is very easy to induce OT with C3H mice.
- Human transferrin was used as antigen.
- 5 Balb/c mice (group A) were given orally 20 mg of transferrin dissolved in 1 ml of isotonic salt serum at 0.9% on day 0.
- the anti-transferrin antibody titre is evaulated by a passive haemagglutination technique according to the method of Johnson et al (Int Arch Allergy 1968, 33, 511-520).
- a group B of 5 Balb/c mice underwent the same treatment, but were given the transferrin by digestive means, i.e. enterally, with 100 mg of a mixture of quail's egg lyophilisate before challenge with transferrin on day 15.
- a control series of 5 mice were given orally 20 mg of bovine albumin with quail's egg lyophilisate; then on day 15 they were given 1 mg of transferrin mixed in 100 ⁇ l of complete Freund's adjuvant (CFA) by injection, finally on day 30 the anti-transferrin antibody titre is evaulated as set out above (group C).
- CFA complete Freund's adjuvant
- Another control group D of 5 Balb/c mice underwent the same treatment as group A but were given fresh chicken's egg instead of quail's egg lyophilisate.
- mice The same experimental pattern was carried out with C3H mice (groups E, F, G, H) and OF1 mice (groups I, J, K, L).
- mice were used in order to show that the induction of a OT with the quail's egg was independent of genetic background.
- the hapten used is DNCB (2,4-dinitrochlorobenzene) obtained from Sigma. This hapten is diluted in a mixture of acetone/olive oil (4 vol / 1 vol). To induce a state of hypersensitivity of contact, after shaving the backs of the mice, a 5% solution of DNCB was applied thereto on day 0. Then, the reaction was revealed 5 days later by application to the ear of a 1% suspension. Finally, the reaction is read 48 hours later by measuring the thickness of the ear with a micrometer. The controlateral ear serving as a control. Under these conditions, a specific DHC is observed, which may be easily evaluated.
- DNCB 2,4-dinitrochlorobenzene
- OT was induced by the ingestion of 500 ⁇ l of a 1.25% suspension of DNCB with or without 100 mg of quail's egg 7 days before immunisation.
- the following table summarises the results of the groups of 5 mice. The values indicate the difference in thickness in mm between the test ear and the reference ear.
- AIHAi autoimmune haemolvtic anaemia
- the intraperitoneal injection of 10 8 rat erythrocytes once per week for 4 to 5 weeks causes AIHA of the mouse with the presence of auto-antibodies and anti rat- erythrocyte xeno-antibodies.
- This AIHA occurs with 100% of the animals (group A). If 10 9 rat erythrocytes are ingested 3 days before each of the injections, a reduction in the number of animals affected by AIHA is obtained (60%) with titres a little lowered (group B).
- Balb/c mice are resistant to the induction of OT according to standard procedures. They even have an anaphylactic shock at the moment of ingestion of the antigen if, first of all, they have been immunised with it. In a series of experiments, it was demonstrated that the antigen (human transferrin) mixed with the quail's egg induces OT in these mice. On the other hand, the same ingestion with immunised animals no longer induces anaphylactic shock.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Polymers & Plastics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Composition pour administration entérale, qui comporte un lyophilisat d'÷uf de caille, caractérisée par le fait que ledit lyophilisat est produit en présence de 5 à 40 % en poids d'hydrate de carbone, sur la base de la teneur en ÷uf de caille en poids. La présente invention concerne l'utilisation d'÷uf de caille ou de ladite composition dans la préparation d'un médicament ou d'une composition nutritionnelle destinée à induire la tolérance orale chez les mammifères, l'÷uf de caille ou ladite composition améliorant la tolérance orale.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU50042/96A AU5004296A (en) | 1995-03-09 | 1996-03-08 | Composition for oral tolerance induction and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9502958A FR2731353A1 (fr) | 1995-03-09 | 1995-03-09 | Utilisation de l'oeuf de caille ou de ses derives ajoute a un antigene comme adjuvant de l'induction d'une tolerance par voie orale ou aerienne pour le traitement des maladies a composantes immunitaires |
FR95/02958 | 1995-03-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996028176A1 true WO1996028176A1 (fr) | 1996-09-19 |
Family
ID=9477020
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1996/001004 WO1996028176A1 (fr) | 1995-03-09 | 1996-03-08 | Composition destinee a induire la tolerance orale et utilisation de ladite composition |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU5004296A (fr) |
FR (1) | FR2731353A1 (fr) |
WO (1) | WO1996028176A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2810550B1 (fr) * | 2000-06-27 | 2004-10-08 | Medibrevex | Nouvelle formes galeiques solubles d'oeufs de caille a usage medicamenteux pour lavage oculaire et nasale et leurs procedes de fabrication |
FR2811898B1 (fr) * | 2000-07-18 | 2003-12-12 | Medibrevex | Formes galeniques medicamenteuses homeopathiques d'allergenes impregnes sur un support biologiquement actif pour desensibilisation specifique par voie sublinguale et leur procede de fabrication |
FR2813531B1 (fr) * | 2000-09-06 | 2003-02-14 | Medibrevex | Formes galeniques d'oligoelements incorpores dans un excipient biologiquement actif d'homogenat d'oeufs de caille et leur procede de fabrication |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2356426A1 (fr) * | 1976-06-29 | 1978-01-27 | Truffier Jean Claude | Fraction ovomucoide du blanc de l'oeuf de caille, ayant des proprietes antiproteasiques |
EP0032344A2 (fr) * | 1979-12-28 | 1981-07-22 | Jean-Claude Truffier | Lyophilisat d'oeuf de caille pour le traitement des maladies immuno-allergiques |
FR2489690A1 (fr) * | 1979-05-07 | 1982-03-12 | Coturnix | Procede d'obtention de la fraction ovomucoide et d'un extrait d'ovomucoide de l'oeuf de caille, produits ainsi obtenus et leur application a titre de medicament |
WO1989011297A1 (fr) * | 1988-05-27 | 1989-11-30 | Centocor, Inc. | Preparation lyophilisee pour la stabilisation de produits a base d'anticorps |
-
1995
- 1995-03-09 FR FR9502958A patent/FR2731353A1/fr active Pending
-
1996
- 1996-03-08 AU AU50042/96A patent/AU5004296A/en not_active Abandoned
- 1996-03-08 WO PCT/EP1996/001004 patent/WO1996028176A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2356426A1 (fr) * | 1976-06-29 | 1978-01-27 | Truffier Jean Claude | Fraction ovomucoide du blanc de l'oeuf de caille, ayant des proprietes antiproteasiques |
FR2489690A1 (fr) * | 1979-05-07 | 1982-03-12 | Coturnix | Procede d'obtention de la fraction ovomucoide et d'un extrait d'ovomucoide de l'oeuf de caille, produits ainsi obtenus et leur application a titre de medicament |
EP0032344A2 (fr) * | 1979-12-28 | 1981-07-22 | Jean-Claude Truffier | Lyophilisat d'oeuf de caille pour le traitement des maladies immuno-allergiques |
WO1989011297A1 (fr) * | 1988-05-27 | 1989-11-30 | Centocor, Inc. | Preparation lyophilisee pour la stabilisation de produits a base d'anticorps |
Non-Patent Citations (1)
Title |
---|
J. BENVENISTE: "GUÉRIR L'ALLERGIE.", LA RECHERCHE, vol. 10, no. 104, October 1979 (1979-10-01), PARIS FR, pages 1012 - 1013, XP002005328 * |
Also Published As
Publication number | Publication date |
---|---|
FR2731353A1 (fr) | 1996-09-13 |
AU5004296A (en) | 1996-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0603992B1 (fr) | Administration orale de biomolécules à activité immunologique et d'autres protéines à activité thérapeutique | |
US9409996B2 (en) | Treatment of food intolerance and food allergy with IgM | |
KR100365252B1 (ko) | 위장 손상의 치료 방법 | |
US20130095093A1 (en) | Methods and compositions for treatment of immune dysfunction disorders | |
US20080213263A1 (en) | Methods and compositions for treatment of immune dysfunction disorders | |
CZ298215B6 (cs) | Lécivo pro lécení chronických poruch centrálního nervového systému, potravinový doplnek a farmaceutická kompozice, obsahující kolostrinin nebo z nehoodvozený nanopeptid | |
EP0904090B1 (fr) | Composition anti-inflammatoire a base d'oeufs, technique d'isolation et usage | |
JP4554728B2 (ja) | 移植片拒絶反応またはアレルギーまたは自己免疫反応と関連した病状を治療するための医薬または食品組成物 | |
EP1085906B1 (fr) | Anticorps anti-il6 utilises en prevention et traitement de maladies intestinales inflammatoires | |
JPS5837285B2 (ja) | チヨウナイカンセンシヨウチリヨウザイノセイゾウホウホウ | |
KR20180027582A (ko) | Af-16 함량이 높은 난황의 제조 방법 | |
US6187803B1 (en) | Drug preparation for oral administration | |
WO1996028176A1 (fr) | Composition destinee a induire la tolerance orale et utilisation de ladite composition | |
CA2317813A1 (fr) | Composition et methode de traitement et de prevention de l'arthrite et/ou de maladies auto-immunes | |
US20060134101A1 (en) | Use of avian antibodies | |
JP2005502597A (ja) | 韓国産エゾウコギ抽出物、これに由来する抽出蛋白質及び粗蛋白多糖類、そしてこれを有効成分とする免疫調節用組成物及びその用途 | |
JPH0669962B2 (ja) | 経口免疫グロブリン | |
JP5047431B2 (ja) | 炎症を低減させるグルコサミンおよび卵 | |
EP0032344B1 (fr) | Lyophilisat d'oeuf de caille pour le traitement des maladies immuno-allergiques | |
Hoenig et al. | Suppression of humoral immune response in mice by administration of high molecular levan | |
AU772785B2 (en) | Anti-diarrheal and method for using the same | |
CA1332222C (fr) | Composition pharmaceutique pour la prevention et le traitement des maladies causees par une deficience immunitaire primaire | |
WO2021162563A1 (fr) | Lipopolysaccharides pour le traitement d'allergies alimentaires | |
CN117440818A (zh) | 用于治疗或预防酒精性肝病和移植物抗宿主病的超免疫的蛋制品 | |
BOYCE | Primary Immunodeficiencies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |